Fears that the coronavirus vaccine won’t be enough to keep many cancer patients safe after one in 10 doesn’t produce high levels of antibodies. even after the second injection
- A new study compares cancer patients who received two doses of the Pfizer-BioEntech vaccine with a control group.
- Israeli scientists found that 10% of cancer patients who received the COVID-19 vaccine did not develop as many antibodies as everyone in the control group did.
- All cancer patients developed fewer antibodies than their peers in the control group.
- What do the results mean for people with idiopathic cancer? This is because researchers are unable to conclude whether lower antibody levels make them less safe from COVID-19.
Many cancer patients may still be at risk of COVID-19 even after completing vaccinations. After a new study, 1 in 10 had low antibody levels. despite having received two vaccines
The researchers compared the antibody responses of cancer patients to the responses of cancer patients after two shots of the Pfizer-BioNTech vaccine.
15 Israeli scientists, led by researchers at the Israeli Institute of Technology, found that about 10 percent of cancer patients had no mass antibody responses after vaccination. may infect them.
A lower antibody response was seen in patients with leukemia. But not in patients with melanoma.
Blood tests indicate that cancer patients have lower antibody responses than the general population. And people with blood cancer in particular are at risk of developing lower antibody levels than their peers.
10 percent of cancer patients in this study did not have a high antibody response after vaccination. Every member of the control group does.
For the study published in JAMA Oncology, 102 cancer patients and 78 control group members were recruited, consisting of family and friends of cancer patients.
The median age of cancer patients was 66, while the median age of the control group was 62.
Patients in the research group had previously used several therapies to fight cancer. But those receiving immunosuppressive therapy were not eligible for the study.
Gastrointestinal, lung, and breast cancer were the most common types of cancer in the research group.
A total of 78 control group members tested high levels of antibodies for the COVID-19 virus. For more than 12 days after a second shot of Pfizer vaccine.
However, of the 102 cancers, only 90 had high levels of antibodies in the blood tests.
Moreover The antibody levels of cancer patients overall were also significantly lower than in the control group.
The researchers said It is not yet known whether certain levels of antibodies make safer antibodies to the virus. or make a person safer for longer More studies are needed to determine what are acceptable levels of antibodies.
They also believed that all vaccinated cancer patients were as safe from the virus as in the control group. and advise everyone to get vaccinated when possible. especially those who may be at greater risk from COVID, such as cancer patients.
The author wrote that “however Our findings suggest that vaccinating such patients during the treatment of all cancers should be of the utmost importance.”
Researchers continue to recommend cancer patients get vaccinated to protect themselves from Covid-19. The number of Americans vaccinated weekly is slowly dropping. during the past month
According to the Centers for Disease Control and Prevention (CDC), about 50 percent of Americans are vaccinated against COVID-19. at least once More than 60 percent of adults are at least partially vaccinated.
Dr. Anthony Fauci, one of the country’s leading infectious disease specialists. believe that the country can prevent the spread of COVID-19 all in the future If at least 70 percent of adults get their first shot. Following the goals of President Joe Biden
America is on track to achieve that goal by July 4, according to Fauci, but only if current vaccination rates continue for another month.